Summary
Hepatitis B (HBV) and C virus (HCV) are the most important etiologic agents of Hepatocellular carcinoma (HCC), which is the second leading cause of tumour related death in the world. The burden of HCC in developing countries represents a major challenge in global public health for the oncoming decades. Clinically, HCC patients have a very poor prognosis and high 5-year mortality rate except when detected early. As a result, HCC early detection is a critical parameter to anticipate the initiation of a tumour process, but affordable and discriminant diagnostic tools are lacking.
A consortium of European and Third Countries institutions (Peru and Laos) gathered within the project COCLICAN proposes to tackle this issue through the analysis of metabolomics serum profiles of a large cohort of HBV-HBC infected patients to delineate a bunch of molecules predictive of the emergence of liver cancer. The performance of a low-cost and open-source echo-stethoscope connected to a smartphone will also be assessed, to allow early detection of tumorogenesis in health care underserved areas.
This will be possible, thanks to the construction of a sustainable scientific and academic network of engineers, researchers and clinicians mobilised to exchange expertise, skills, technologies, biological material, deployed in three continents: Europe, South America and Asia.
COCLICAN has been designed to improve research collaborations, to reinforce capacities, to enhance knowledge of partners and students involved in the project, but also to raise awareness of policy makers and to participate to the innovation potential improvement at the European and global levels. COCLICAN will therefore respond to the health needs of left behind populations, all around the world.
A consortium of European and Third Countries institutions (Peru and Laos) gathered within the project COCLICAN proposes to tackle this issue through the analysis of metabolomics serum profiles of a large cohort of HBV-HBC infected patients to delineate a bunch of molecules predictive of the emergence of liver cancer. The performance of a low-cost and open-source echo-stethoscope connected to a smartphone will also be assessed, to allow early detection of tumorogenesis in health care underserved areas.
This will be possible, thanks to the construction of a sustainable scientific and academic network of engineers, researchers and clinicians mobilised to exchange expertise, skills, technologies, biological material, deployed in three continents: Europe, South America and Asia.
COCLICAN has been designed to improve research collaborations, to reinforce capacities, to enhance knowledge of partners and students involved in the project, but also to raise awareness of policy makers and to participate to the innovation potential improvement at the European and global levels. COCLICAN will therefore respond to the health needs of left behind populations, all around the world.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/823935 |
| Start date: | 01-11-2018 |
| End date: | 31-10-2022 |
| Total budget - Public funding: | 450 800,00 Euro - 450 800,00 Euro |
Cordis data
Original description
Hepatitis B (HBV) and C virus (HCV) are the most important etiologic agents of Hepatocellular carcinoma (HCC), which is the second leading cause of tumour related death in the world. The burden of HCC in developing countries represents a major challenge in global public health for the oncoming decades. Clinically, HCC patients have a very poor prognosis and high 5-year mortality rate except when detected early. As a result, HCC early detection is a critical parameter to anticipate the initiation of a tumour process, but affordable and discriminant diagnostic tools are lacking.A consortium of European and Third Countries institutions (Peru and Laos) gathered within the project COCLICAN proposes to tackle this issue through the analysis of metabolomics serum profiles of a large cohort of HBV-HBC infected patients to delineate a bunch of molecules predictive of the emergence of liver cancer. The performance of a low-cost and open-source echo-stethoscope connected to a smartphone will also be assessed, to allow early detection of tumorogenesis in health care underserved areas.
This will be possible, thanks to the construction of a sustainable scientific and academic network of engineers, researchers and clinicians mobilised to exchange expertise, skills, technologies, biological material, deployed in three continents: Europe, South America and Asia.
COCLICAN has been designed to improve research collaborations, to reinforce capacities, to enhance knowledge of partners and students involved in the project, but also to raise awareness of policy makers and to participate to the innovation potential improvement at the European and global levels. COCLICAN will therefore respond to the health needs of left behind populations, all around the world.
Status
CLOSEDCall topic
MSCA-RISE-2018Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (Coördinator)
-
| ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
-
| FONDATION MERIEUX
-
| INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-INEN
-
| KAUNO TECHNOLOGIJOS UNIVERSITETAS
-
| MINISTRY OF HEALTH
-
| UNIVERSITE LIBRE DE BRUXELLES
-
| UNIVERSITE PAUL SABATIER TOULOUSE III